Other Events ·
NeOnc Technologies Holdings announced positive topline results from the Phase 2a portion of its NEO100-01 study in…
NTHINeonc Technologies Holdings, Inc.
NeOnc Technologies Holdings announced positive topline results from the Phase 2a portion of its NEO100-01 study in patients with recurrent IDH1-mutant high-grade glioma. The trial met its primary endpoint, achieving a six-month progression-free survival rate of 48.9% against a pre-specified 20% benchmark (p = 0.0047). Median overall survival was 26.09 months, with an 86.7% survival rate at six months and no major toxicities reported. The company plans to request a Type B meeting with the FDA to align on a registrational path for a Phase 3 study. NeOnc Technologies Holdings is a clinical-stage biopharmaceutical company developing novel therapies for central nervous system cancers.